News & Updates

Show Multimedia Only

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

04 Sep 2026 by

In patients with serious mental illness (SMI), initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with lower risks of all-cause mortality and major adverse cardiovascular events (MACEs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors, a large study has shown.

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

04 Sep 2026

Original New Drug Application Approvals by US FDA (1-15 August 2026)

03 Sep 2026

New drug applications approved by US FDA as of 1-15 August 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 August 2026)

03 Sep 2026

Continuous clozapine use may reduce suicide deaths in schizophrenia

02 Sep 2026 by

Continued treatment with clozapine has been associated with a lower the risk of suicide mortality among patients with schizophrenia in Hong Kong.

Continuous clozapine use may reduce suicide deaths in schizophrenia

02 Sep 2026

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

01 Sep 2026

Patient satisfaction is high during the first year following penile inversion vaginoplasty for functional outcomes and alleviation of gender dysphoria, a study has shown.

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

01 Sep 2026

Evolving patterns of antipsychotic use for schizophrenia over 21 years in HK

31 Aug 2026 by

Over the last two decades, antipsychotic prescriptions for patients with schizophrenia shifted notably toward second-generation antipsychotics (SGAs), regardless of formulation, and antipsychotic polypharmacy became more prevalent, although overall use of antipsychotics remained stable, a 21-year longitudinal study has shown.

Evolving patterns of antipsychotic use for schizophrenia over 21 years in HK

31 Aug 2026

East Asian herbal medicine may have therapeutic potential in schizophrenia

30 Aug 2026

Use of East Asian herbal medicine as an adjunct to antipsychotics may help improve symptoms and reduce adverse events in patients with schizophrenia, according to a meta-analysis.

East Asian herbal medicine may have therapeutic potential in schizophrenia

30 Aug 2026

Cannabis-associated psychosis linked to better cognitive function, but use may cause relapse

28 Aug 2026

Males hospitalized for new-onset psychosis with confirmed cannabis exposure (CAP) demonstrate better cognitive function, lower cortical excitatory/inhibitory (E/I) balance, fewer negative symptoms, and greater improvement in mood symptoms than those with noncannabis-associated psychosis (NCAP), a study has shown. However, resuming cannabis use may result in relapse.

Cannabis-associated psychosis linked to better cognitive function, but use may cause relapse

28 Aug 2026

Gene deletions tied to poor cognition in schizophrenia patients

27 Aug 2026

Several copy number variants (CNVs) contribute to severe phenotypes in schizophrenia spectrum disorders (SSDs), and disruptions in foetal brain development are associated with poor cognition, suggests a study.

Gene deletions tied to poor cognition in schizophrenia patients

27 Aug 2026

Second-hand smoke exposure further increases depression risk in smokers

21 Aug 2026

Middle aged and older adults who actively smoke are at increased risk of depressive symptoms, and exposure to second-hand smoke further increases this risk, according to a 20-year prospective cohort study.

Second-hand smoke exposure further increases depression risk in smokers

21 Aug 2026

News & Updates

Showing Psychiatry articles

Showing

Specialty:

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

Original New Drug Application Approvals by US FDA (1-15 August 2026)

Original New Drug Application Approvals by US FDA (1-15 August 2026)

Continuous clozapine use may reduce suicide deaths in schizophrenia

Continuous clozapine use may reduce suicide deaths in schizophrenia

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

Evolving patterns of antipsychotic use for schizophrenia over 21 years in HK

Evolving patterns of antipsychotic use for schizophrenia over 21 years in HK

East Asian herbal medicine may have therapeutic potential in schizophrenia

East Asian herbal medicine may have therapeutic potential in schizophrenia

Cannabis-associated psychosis linked to better cognitive function, but use may cause relapse

Cannabis-associated psychosis linked to better cognitive function, but use may cause relapse

Gene deletions tied to poor cognition in schizophrenia patients

Gene deletions tied to poor cognition in schizophrenia patients

Second-hand smoke exposure further increases depression risk in smokers

Second-hand smoke exposure further increases depression risk in smokers